Perceptive Advisors’s CASI Pharmaceuticals CASI Stock Holding History

Perceptive Advisors’s Portfolio CASI Stock Details CASI Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2018 Q4	–	Sell	-4,368	Closed	-$204K	–	106
2018 Q3	$204K	Hold	4,368	–	–	0.01%	112
2018 Q2	$360K	Hold	4,368	–	–	0.01%	114
2018 Q1	$182K	Sell	4,368 -4,000	-48%	-$149K	0.01%	133
2017 Q4	$272K	Buy	+8,368	New	+$227K	0.01%	127

Other funds holding CASI

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

WSCM

Wellington Shields Capital Management New York $788M AUM 66.95% 1-Year Est. Return

WSC

Wellington Shields & Co New York $446M AUM 38.92% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Northern Trust Chicago, Illinois $860B AUM 41.15% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Charles Schwab San Francisco, California $751B AUM 38.74% 1-Year Est. Return

ALPS Advisors Denver, Colorado $21.3B AUM 23.41% 1-Year Est. Return

Bank of New York Mellon New York $609B AUM 40.19% 1-Year Est. Return

Perceptive Advisors's CASI Position: Q4 2018 in Review

Perceptive Advisors sold out of CASI Pharmaceuticals (CASI) in Q4 2018, closing a stake of 4,368 shares — an estimated $204K sold.

Perceptive Advisors first reported a position in CASI in Q4 2017 and held it in 4 quarters. The position peaked at $360K in Q2 2018. 54 funds tracked by Wall St. Rank hold CASI as of Q4 2018.

Perceptive Advisors reported no remaining CASI Pharmaceuticals position as of Q4 2018 after selling out during the quarter.
Perceptive Advisors sold 4,368 CASI Pharmaceuticals shares in Q4 2018, an estimated $204K.
Perceptive Advisors first reported a position in CASI Pharmaceuticals in Q4 2017 and held it in 4 quarters.
Perceptive Advisors's CASI Pharmaceuticals position peaked at $360K in Q2 2018.
54 funds tracked by Wall St. Rank held CASI Pharmaceuticals as of Q4 2018.

Based on Perceptive Advisors's 13F filing for Q4 2018, filed 14 Feb 2019.